Losartan Potassium Tablet, Film Coated
Product Images NDC 87441-052

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 87441-052). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Losartan 25 mg (8744105201 Losartan Potassium 25 mg)

Losartan 25 mg (8744105201 Losartan Potassium 25 mg)
Losartan Potassium Tablets, USP are prescription drugs with a strength of 25mg. They should be stored at a temperature between 20°C to 25°C (68°F to 77°F). Dispensed by pharmacists, each tablet contains Losartan Potassium USP and must be kept out of children's reach. This medication is repackaged by Unit Dose Solutions, INC. and distributed by Tuckhoe Enterprises, LLC.*
FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical Structure (Spl Image1 Structure1)
FDA Label Image

Figure 1 (Spl Image2 Figure1)

Figure 1 (Spl Image2 Figure1)
This text shows a comparison between Atenolol and Losartan Potassium in reducing the risk of the primary endpoint in patients. The study reveals an adjusted risk reduction of 13% with a p-value of 0.021 over a span of 66 study months.*
FDA Label Image

Figure 2 (Spl Image3 Figure2)

Figure 2 (Spl Image3 Figure2)
This text provides information related to a medication change from Atenolol to Losartan Potassium, displaying an adjusted risk reduction of 25% with a significance level of p=0.001. It also shows the percentage of patients with fatal/non-fatal stroke over study months from 6 to 66.*
FDA Label Image

Figure 3 (Spl Image4 Figure3)

Figure 3 (Spl Image4 Figure3)
This text provides data on primary endpoint events within demographic subgroups in a medical study comparing the effectiveness of Losartan and Atenolol in preventing strokes, including fatal and non-fatal strokes. The subgroups analyzed include age, gender, race, presence of isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). Results are presented in terms of the number of events, rates, and hazard ratios with corresponding confidence intervals. The analysis is adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy. Sample sizes of the subgroups are indicated by proportional symbols. The study considers different demographic backgrounds, such as Black, White, and other races like Asian, Hispanic, and Native American.*
FDA Label Image

Figure 4 (Spl Image5 Figure4)

Figure 4 (Spl Image5 Figure4)
This text shows the results of a study comparing Losartan Potassium to a Placebo in patients with an event. The risk reduction with Losartan Potassium compared to Placebo is 16.1%, with a p-value of 0.022. The timeline spans from 0 to 48 months, and the data suggests a benefit of using Losartan Potassium over Placebo in reducing the risk of the event.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.